FrontPoint Named As Recipient Of Insider Info

Nov 3 2010 | 3:03am ET

FrontPoint Partners is the, until now, unidentified hedge fund that allegedly received inside information from a French doctor charged yesterday by U.S. authorities.

According to the Securities and Exchange Commission's complaint, Yves Benhamou used his position as an adviser to pharmaceutical company Human Genome to pass confidential information on the results of a hepatitis-C drug trial to at least six hedge funds. Those six hedge funds sold 6 million shares of Human Genome in December 2007 and January 2008 while in possession of confidential, negative information about those drug trials, the SEC said.

FrontPoint, which is being spun off from Morgan Stanley, sold all 3.3 million shares of Human Genome it owned in the first quarter of 2008, although it is unclear when the hedge fund sold those shares. Human Genome broke the bad news about the drug testing on Jan. 23, 2008, sending its stock price plummeting 44%.

FrontPoint has not been charged with any wrongdoing, although it has placed Chip Skowron, the co-portfolio manager of its health care hedge funds, on leave until the investigation is resolved. FrontPoint said it was "cooperating fully" with the authorities.

Benhamou was arrested on Monday in Boston on two criminal charges.


In Depth

Malik: The Science of Deal Sourcing 201

Aug 27 2015 | 5:35pm ET

Deal sourcing is understandably a hot topic among private equity firms because it...

Lifestyle

Rolling Art Advisors Marketing Collectible Car Fund As Uncorrelated Alternative

Aug 27 2015 | 6:47pm ET

A new fund is trying to provide investors with greater access to an emerging asset...

Guest Contributor

Agecroft Partners: Hedge Fund Industry Assets to increase $250B by Summer 2016

Aug 11 2015 | 11:29am ET

Assets will continue to flow into the hedge fund industry despite long-standing...

 

Editor's Note